Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant Therapy with High-Dose Medroxyprogesterone Acetate for Operable Breast Cancer.

Koyama1

  • 1Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka 537-8511, Japan.

Breast Cancer (Tokyo, Japan)
|November 25, 2000
PubMed
Summary

Medroxyprogesterone acetate (MPA) combined with fluorouracil is a safe adjuvant therapy for breast cancer patients, showing good disease-free survival rates. This treatment demonstrated acceptable morbidity in selected patients, with manageable side effects like abnormal menstruation and weight gain.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory Cancer of the Breast: Present Situation and Future Prospect.

Breast cancer (Tokyo, Japan)·2000
Same author

Prospective Randomized Study of Cyclophosphamide, Epirubicin, and 5-Fluorouracil versus Cyclophosphamide, Adriamycin, and 5-Fluorouracil in Advanced or Recurrent Breast Cancer.

Breast cancer (Tokyo, Japan)·2000
Same author

Sentinel Node Biopsy in Breast Cancer Patients with Clinically Negative Lymph-Nodes.

Breast cancer (Tokyo, Japan)·2000
Same author

Sentinel Node Biopsy in Breast Cancer.

Breast cancer (Tokyo, Japan)·2000
Same author

X-Ray anomalous scattering study of a charge-ordered state in NaV2O5

Physical review letters·2000
Same author

[An adult case of mumps brainstem encephalitis] [In Process Citation]

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·2000

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Medroxyprogesterone acetate (MPA) shows comparable or superior response rates in metastatic breast cancer versus tamoxifen.
  • Previous Western studies suggest MPA efficacy as an adjuvant therapy post-surgery for specific breast cancer patient subsets.
  • This multicenter open study in Japan evaluated MPA's safety and efficacy in adjuvant endocrine therapy.

Purpose of the Study:

  • To investigate the safety and efficacy of medroxyprogesterone acetate (MPA) as an adjuvant endocrine therapy for breast cancer patients in Japan.
  • To assess the morbidity and disease-free survival rates associated with MPA combined with a fluorouracil compound postoperatively.

Main Methods:

  • A total of 119 patients with stage II or IIIa breast cancer received 800 mg/day MPA plus a fluorouracil compound for 6 months postoperatively.

Related Experiment Videos

  • The study was conducted across 32 hospitals in Japan between June 1987 and June 1989.
  • Median follow-up was 74.5 months (range, 2.2-90.0 months).

    • Main Results:

    • 49.6% of patients experienced adverse reactions, most commonly abnormal menstruation (premenopausal) and vaginal bleeding (postmenopausal).
    • Weight gain (19.3%) and moon face (7.6%) were also noted. Treatment discontinuation occurred in 14.3% of patients, primarily due to weight gain.
    • No severe adverse reactions were observed. Disease-free survival rates at 5 years were 82.6% for stage II and 52.9% for stage IIIa patients.

    Conclusions:

    • Medroxyprogesterone acetate (MPA) at 800 mg/day plus a fluorouracil compound is a safe adjuvant treatment option for selected breast cancer patients.
    • The combination therapy demonstrated acceptable morbidity and promising disease-free survival rates.
    • Adjuvant MPA therapy offers a viable endocrine treatment strategy for specific breast cancer populations.